**FOR IMMEDIATE RELEASE**

**Media Contact:**   
Name and Title  
Phone Number  
Email

**Practice Name Now Offers Patients an Early Warning System for Their Eyes with the ForeseeHome® AMD Home Monitoring Program**  
*Cutting-edge diagnostic monitoring system now part of our practice’s personalized approach to managing many of our dry AMD patients.*

**CITY, STATE – DATE** – In striving to provide the latest technological advances in patient care, Practice Name is proud and excited to prescribe ForeseeHome, the first FDA-cleared home-monitoring device, to patients with certain types of dry Age-related Macular Degeneration (AMD) at risk for developing wet AMD.

The ForeseeHome AMD Monitoring Program allows patients with dry AMD to test their vision from the comfort of home and provides eye care professionals the ability to monitor their patients between office visits. Patients’ testing data are analyzed on the device and then automatically transmitted to the Notal Vision Diagnostic Clinic, whose medical staff review the data before reporting it to the prescribing doctor, enabling timely assessment of the patient should any significant changes in vision be detected. ForeseeHome is available to patients with a prescription from their eye doctor and most insurers cover some or all of the cost of the program.

AMD is the most common cause of blindness in the United States. There are two types, dry and wet. Dry AMD puts patients at an increased risk of progressing to wet AMD, which can lead to rapid and severe vision loss.

“Early detection of wet AMD significantly increases a doctor’s ability to help preserve a patient’s vision,” says Practice Representative with title. “We decided to offer this technology because it allows both our doctors and patients to be as proactive as possible in protecting the patient’s vision”

**About Practice**

Insert Practice boiler plate

**About ForeseeHome**

ForeseeHome is the first FDA-cleared home-monitoring device for patients with intermediate dry AMD at risk for developing wet AMD. ForeseeHome uses a patented technology, Preferential Hyperacuity Perimetry (PHP), that can identify minute changes in the central visual field often before the patient has any significant visual symptoms. During the test, which takes 3-5 minutes, a total of 500 data points are evaluated 3-5 times across the central 14 degrees of the macula to detect statistically significant changes in metamorphopsia, distortion of the vision. These ForeseeHome testing results are automatically sent to the Notal Vision Diagnostic Clinic. If there is a significant change in metamorphopsia, the adaptive test will generate an alert which is provided to the patient’s eye doctor by the diagnostic clinic. Their doctor can then determine if a patient should be evaluated to determine if there is a conversion from dry to wet AMD, in some cases before a patient is even aware of any visual changes.

ForeseeHome’s clinical utility was established in the Home Monitoring of The Eye (HOME) Study, part of the National Eye Institute-sponsored AREDS2 study, in which 94% of patients using ForeseeHome at least twice weekly in addition to regularly scheduled eye exams and who progressed to wet AMD, maintained 20/40 or better vision compared to only 62% of patients whose diagnosis was at a routine eye exam or a visit triggered by symptoms. The HOME study was halted at the interim analysis because patients using ForeseeHome demonstrated significantly better vision at choroidal neovascularization (CNV) detection compared with standard care. Based on level-1 evidence and compelling clinical outcomes demonstrating the ability to detect CNV while patients retained functional vision, ≥20/40, the ForeseeHome AMD Monitoring Program gained Medicare coverage in 2016.

ForeseeHome is the first application of Notal Vision’s cloud-based monitoring platform. The company is developing a second product, home-based optical coherence tomography (OCT) testing, that will also leverage the platform.

**About the AREDS2 HOME study**

The AREDS2 (Age Related Eye Disease Study 2) HOME (Home Monitoring of the Eye) study, a phase 3, randomized, controlled trial of 1,520 dry AMD patients, compared VA at the time of CNV diagnosis between at-risk patients randomized to use the ForeseeHome device plus standard care (self-monitoring and routine clinic visits) and patients utilizing standard care alone. Of the patients who tested with ForeseeHome at least twice a week, 94% maintained 20/40 or better visual acuity, compared with 62% of eyes in the standard care arm (P=0.014). In addition, those same patients lost significantly fewer letters when compared with the standard care arm (-3 letters and -9 letters, respectively, *P*=0.003) when the alert was triggered between prescheduled office visits. Wet AMD was 16 times more likely to be detected from a visit triggered by ForeseeHome versus a pre-scheduled visit, and the lesions were ~300% larger at diagnosis when detected during a routine office visit versus a ForeseeHome-triggered visit. The HOME study was halted at the interim analysis because patients using ForeseeHome demonstrated significantly better vision at detection compared to standard care alone.

**About Notal Vision, Inc.**

Notal Vision was founded by two ophthalmologists and is committed to providing the eyecare community with innovative, home-based, diagnostic technologies that support visual health in patients with retinal diseases. ForeseeHome is the first FDA-cleared remote diagnostic testing device that detects and characterizes visual distortion in AMD patients as an aid to monitoring for the development of choroidal neovascularization. To learn more, visit www.notalvision.com.

###